Modelling PK/QT relationships from Phase I dose-escalation trials for drug combinations and developing quantitative risk assessments of clinically relevant QT prolongations.
about
Modelling PK/QT relationships from Phase I dose-escalation trials for drug combinations and developing quantitative risk assessments of clinically relevant QT prolongations.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Modelling PK/QT relationships ...... lly relevant QT prolongations.
@en
Modelling PK/QT relationships ...... lly relevant QT prolongations.
@nl
type
label
Modelling PK/QT relationships ...... lly relevant QT prolongations.
@en
Modelling PK/QT relationships ...... lly relevant QT prolongations.
@nl
prefLabel
Modelling PK/QT relationships ...... lly relevant QT prolongations.
@en
Modelling PK/QT relationships ...... lly relevant QT prolongations.
@nl
P2093
P2860
P356
P1476
Modelling PK/QT relationships ...... lly relevant QT prolongations.
@en
P2093
Jixian Wang
Kai Grosch
Karen Sinclair
P2860
P304
P356
10.1002/PST.1747
P50
P577
2016-03-17T00:00:00Z